FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2012-08-28

AUTHORS

Zuo-Lin Xiang, Jeremy Erasmus, Ritsuko Komaki, James D Cox, Joe Y Chang

ABSTRACT

BackgroundWe studied whether maximum standardized uptake values (SUV) from [18 F] PET/CT predict clinical outcome after concurrent proton/chemotherapy for stage III non-small cell lung cancer (NSCLC).MethodsEighty-four patients were treated prospectively with 74 Gy(RBE) proton therapy and concurrent chemotherapy. PET/CT scans were available before (SUV1) and within 6 months after (SUV2) treatment. The predictive value of clinical and PET/CT factors were analyzed with univariate and multivariate Cox regression models.ResultsMedian survival time was 29.9 months. At 3 years, the local recurrence-free survival (LRFS) rate was 34.8%; distant metastasis-free survival (DMFS), 35.4%; progression-free survival (PFS), 31.2%; and overall survival (OS), 37.2%. Patients with SUV2 ≥3.6 (the median) had high rates of LR (p = 0.021). Of 12 clinicopathologic features evaluated in univariate analysis, only KPS, SUV1, and SUV2 predicted LRFS, DMFS, PFS, and OS (p <0.05). Multivariate analysis showed that KPS (p = 0.025) and SUV2 (p = 0.017) were independently prognostic for LRFS and that SUV1, SUV2, and KPS were independently prognostic for DMFS, PFS, and OS (p <0.05).ConclusionsSUV2 predicted LRFS, and SUV1 and SUV2 predicted DMFS, PFS, and OS, in patients with stage III NSCLC treated with concurrent chemotherapy and high-dose proton therapy. More... »

PAGES

144

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1748-717x-7-144

DOI

http://dx.doi.org/10.1186/1748-717x-7-144

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1029399807

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22929048


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorodeoxyglucose F18", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multimodal Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron-Emission Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proton Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tomography, X-Ray Computed", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xiang", 
        "givenName": "Zuo-Lin", 
        "id": "sg:person.01255207421.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255207421.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Departments of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Erasmus", 
        "givenName": "Jeremy", 
        "id": "sg:person.01006443300.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006443300.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Komaki", 
        "givenName": "Ritsuko", 
        "id": "sg:person.07500134657.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07500134657.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cox", 
        "givenName": "James D", 
        "id": "sg:person.0734411024.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734411024.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chang", 
        "givenName": "Joe Y", 
        "id": "sg:person.014351135104.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014351135104.56"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/1748-717x-4-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035283096", 
          "https://doi.org/10.1186/1748-717x-4-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-08-28", 
    "datePublishedReg": "2012-08-28", 
    "description": "BackgroundWe studied whether maximum standardized uptake values (SUV) from [18\u2009F] PET/CT predict clinical outcome after concurrent proton/chemotherapy for stage III non-small cell lung cancer (NSCLC).MethodsEighty-four patients were treated prospectively with 74\u2009Gy(RBE) proton therapy and concurrent chemotherapy. PET/CT scans were available before (SUV1) and within 6\u2009months after (SUV2) treatment. The predictive value of clinical and PET/CT factors were analyzed with univariate and multivariate Cox regression models.ResultsMedian survival time was 29.9\u2009months. At 3\u2009years, the local recurrence-free survival (LRFS) rate was 34.8%; distant metastasis-free survival (DMFS), 35.4%; progression-free survival (PFS), 31.2%; and overall survival (OS), 37.2%. Patients with SUV2 \u22653.6 (the median) had high rates of LR (p\u2009=\u20090.021). Of 12 clinicopathologic features evaluated in univariate analysis, only KPS, SUV1, and SUV2 predicted LRFS, DMFS, PFS, and OS (p <0.05). Multivariate analysis showed that KPS (p\u2009=\u20090.025) and SUV2 (p\u2009=\u20090.017) were independently prognostic for LRFS and that SUV1, SUV2, and KPS were independently prognostic for DMFS, PFS, and OS (p <0.05).ConclusionsSUV2 predicted LRFS, and SUV1 and SUV2 predicted DMFS, PFS, and OS, in patients with stage III NSCLC treated with concurrent chemotherapy and high-dose proton therapy.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1748-717x-7-144", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2435408", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2438826", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1036451", 
        "issn": [
          "1748-717X"
        ], 
        "name": "Radiation Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "non-small cell lung cancer", 
      "distant metastasis-free survival", 
      "stage III non-small cell lung cancer", 
      "progression-free survival", 
      "high-dose proton therapy", 
      "cell lung cancer", 
      "overall survival", 
      "standardized uptake value", 
      "concurrent chemotherapy", 
      "lung cancer", 
      "unresectable stage III non-small cell lung cancer", 
      "local recurrence-free survival rate", 
      "recurrence-free survival rates", 
      "multivariate Cox regression model", 
      "maximum standardized uptake value", 
      "PET/CT scans", 
      "ResultsMedian survival time", 
      "FDG uptake correlates", 
      "MethodsEighty-four patients", 
      "metastasis-free survival", 
      "Cox regression model", 
      "proton therapy", 
      "PET/CT", 
      "clinical outcomes", 
      "clinicopathologic features", 
      "univariate analysis", 
      "CT scan", 
      "survival time", 
      "uptake value", 
      "chemotherapy", 
      "predictive value", 
      "survival rate", 
      "multivariate analysis", 
      "uptake correlates", 
      "LRFS", 
      "SUV2", 
      "patients", 
      "CT factors", 
      "SUV1", 
      "therapy", 
      "survival", 
      "high rate", 
      "cancer", 
      "KPS", 
      "months", 
      "regression models", 
      "treatment", 
      "BackgroundWe", 
      "recurrence", 
      "CT", 
      "univariate", 
      "outcomes", 
      "scans", 
      "rate", 
      "correlates", 
      "years", 
      "factors", 
      "LR", 
      "analysis", 
      "values", 
      "time", 
      "features", 
      "model"
    ], 
    "name": "FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy", 
    "pagination": "144", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1029399807"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1748-717x-7-144"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22929048"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1748-717x-7-144", 
      "https://app.dimensions.ai/details/publication/pub.1029399807"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_566.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1748-717x-7-144"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1748-717x-7-144'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1748-717x-7-144'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1748-717x-7-144'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1748-717x-7-144'


 

This table displays all metadata directly associated to this object as RDF triples.

249 TRIPLES      21 PREDICATES      111 URIs      102 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1748-717x-7-144 schema:about N0437e4ddbb544e23b025d1566f2f136d
2 N072e3533cb824ef1bbb1043cbddad649
3 N1099158cd42949d989a47b7a843dbe4e
4 N13450771b5fe43598c53a8e7365b3457
5 N1e8ace15e3cc47d797cb40a4437023d0
6 N313aba112218400cbde73a9b2b95bd70
7 N32b64c1bad66450fb48c3b9436880810
8 N3f540a6b199c4495b9564a98eca01b76
9 N429e1a04a6a749b29ef2b1507fd29680
10 N4381fd3eeabc454e9e9097ba55e1f6ab
11 N52ea1276627b4e088c442ddb3e9ac531
12 N6d24941339584136974016bbd2dbcdc9
13 N856534166cd944e68940c5ec494c39af
14 N8d853f27f73049c59243f13a8629faad
15 N95740e22558e462787f8ebc7cd15910b
16 N95ffcd96ccaa463bbb0e3fadf22b1fae
17 Nb2a49fbe767f407386a526556d898dc3
18 Nb502f5384df24b8d9122421517f8c9f6
19 Nb525c098f6694229a0385e72054162c6
20 Ncf11bb1275ac4cc6a7548ce1c53703df
21 Nd92211fce71b49b58b16209c6c665e68
22 Nfcc4fb8730cb412d81b53fd471bf5c4f
23 anzsrc-for:11
24 anzsrc-for:1112
25 schema:author Nccf88d4985ed4d93b5bf96aa6af3e016
26 schema:citation sg:pub.10.1186/1748-717x-4-5
27 schema:datePublished 2012-08-28
28 schema:datePublishedReg 2012-08-28
29 schema:description BackgroundWe studied whether maximum standardized uptake values (SUV) from [18 F] PET/CT predict clinical outcome after concurrent proton/chemotherapy for stage III non-small cell lung cancer (NSCLC).MethodsEighty-four patients were treated prospectively with 74 Gy(RBE) proton therapy and concurrent chemotherapy. PET/CT scans were available before (SUV1) and within 6 months after (SUV2) treatment. The predictive value of clinical and PET/CT factors were analyzed with univariate and multivariate Cox regression models.ResultsMedian survival time was 29.9 months. At 3 years, the local recurrence-free survival (LRFS) rate was 34.8%; distant metastasis-free survival (DMFS), 35.4%; progression-free survival (PFS), 31.2%; and overall survival (OS), 37.2%. Patients with SUV2 ≥3.6 (the median) had high rates of LR (p = 0.021). Of 12 clinicopathologic features evaluated in univariate analysis, only KPS, SUV1, and SUV2 predicted LRFS, DMFS, PFS, and OS (p <0.05). Multivariate analysis showed that KPS (p = 0.025) and SUV2 (p = 0.017) were independently prognostic for LRFS and that SUV1, SUV2, and KPS were independently prognostic for DMFS, PFS, and OS (p <0.05).ConclusionsSUV2 predicted LRFS, and SUV1 and SUV2 predicted DMFS, PFS, and OS, in patients with stage III NSCLC treated with concurrent chemotherapy and high-dose proton therapy.
30 schema:genre article
31 schema:isAccessibleForFree true
32 schema:isPartOf N8393ca669f504c189dbb6f7c958cc2b7
33 N954651e6f8874d3ea4081f4786d0603f
34 sg:journal.1036451
35 schema:keywords BackgroundWe
36 CT
37 CT factors
38 CT scan
39 Cox regression model
40 FDG uptake correlates
41 KPS
42 LR
43 LRFS
44 MethodsEighty-four patients
45 PET/CT
46 PET/CT scans
47 ResultsMedian survival time
48 SUV1
49 SUV2
50 analysis
51 cancer
52 cell lung cancer
53 chemotherapy
54 clinical outcomes
55 clinicopathologic features
56 concurrent chemotherapy
57 correlates
58 distant metastasis-free survival
59 factors
60 features
61 high rate
62 high-dose proton therapy
63 local recurrence-free survival rate
64 lung cancer
65 maximum standardized uptake value
66 metastasis-free survival
67 model
68 months
69 multivariate Cox regression model
70 multivariate analysis
71 non-small cell lung cancer
72 outcomes
73 overall survival
74 patients
75 predictive value
76 progression-free survival
77 proton therapy
78 rate
79 recurrence
80 recurrence-free survival rates
81 regression models
82 scans
83 stage III non-small cell lung cancer
84 standardized uptake value
85 survival
86 survival rate
87 survival time
88 therapy
89 time
90 treatment
91 univariate
92 univariate analysis
93 unresectable stage III non-small cell lung cancer
94 uptake correlates
95 uptake value
96 values
97 years
98 schema:name FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy
99 schema:pagination 144
100 schema:productId N09f946c52e9648bbb4230279641033d3
101 N52dc865819034ab8a52420b533fd86f4
102 N859e971918e346f5b9cb512b6c0bddb1
103 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029399807
104 https://doi.org/10.1186/1748-717x-7-144
105 schema:sdDatePublished 2022-11-24T20:56
106 schema:sdLicense https://scigraph.springernature.com/explorer/license/
107 schema:sdPublisher N8f136c7eb9374b89928ad346509a5aa6
108 schema:url https://doi.org/10.1186/1748-717x-7-144
109 sgo:license sg:explorer/license/
110 sgo:sdDataset articles
111 rdf:type schema:ScholarlyArticle
112 N0437e4ddbb544e23b025d1566f2f136d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Neoplasm Recurrence, Local
114 rdf:type schema:DefinedTerm
115 N072e3533cb824ef1bbb1043cbddad649 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Antineoplastic Agents
117 rdf:type schema:DefinedTerm
118 N09f946c52e9648bbb4230279641033d3 schema:name pubmed_id
119 schema:value 22929048
120 rdf:type schema:PropertyValue
121 N1099158cd42949d989a47b7a843dbe4e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Proton Therapy
123 rdf:type schema:DefinedTerm
124 N13450771b5fe43598c53a8e7365b3457 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Positron-Emission Tomography
126 rdf:type schema:DefinedTerm
127 N1e8ace15e3cc47d797cb40a4437023d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Male
129 rdf:type schema:DefinedTerm
130 N313aba112218400cbde73a9b2b95bd70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Lung Neoplasms
132 rdf:type schema:DefinedTerm
133 N32b64c1bad66450fb48c3b9436880810 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Female
135 rdf:type schema:DefinedTerm
136 N3f540a6b199c4495b9564a98eca01b76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Aged, 80 and over
138 rdf:type schema:DefinedTerm
139 N429e1a04a6a749b29ef2b1507fd29680 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Radiopharmaceuticals
141 rdf:type schema:DefinedTerm
142 N4381fd3eeabc454e9e9097ba55e1f6ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Disease-Free Survival
144 rdf:type schema:DefinedTerm
145 N46af97ead2ac476ca0b1afb5a0074a2e rdf:first sg:person.01006443300.49
146 rdf:rest N9a9fc826aca44818ba1fb0bbc48773a7
147 N52dc865819034ab8a52420b533fd86f4 schema:name dimensions_id
148 schema:value pub.1029399807
149 rdf:type schema:PropertyValue
150 N52ea1276627b4e088c442ddb3e9ac531 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Aged
152 rdf:type schema:DefinedTerm
153 N6d24941339584136974016bbd2dbcdc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Kaplan-Meier Estimate
155 rdf:type schema:DefinedTerm
156 N74d6bb825ae1410dad02701c8ac5dec5 rdf:first sg:person.0734411024.14
157 rdf:rest Nf5307e6b27a14aa89687ecdcf04b4ae8
158 N8393ca669f504c189dbb6f7c958cc2b7 schema:issueNumber 1
159 rdf:type schema:PublicationIssue
160 N856534166cd944e68940c5ec494c39af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Neoplasm Staging
162 rdf:type schema:DefinedTerm
163 N859e971918e346f5b9cb512b6c0bddb1 schema:name doi
164 schema:value 10.1186/1748-717x-7-144
165 rdf:type schema:PropertyValue
166 N8d853f27f73049c59243f13a8629faad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Combined Modality Therapy
168 rdf:type schema:DefinedTerm
169 N8f136c7eb9374b89928ad346509a5aa6 schema:name Springer Nature - SN SciGraph project
170 rdf:type schema:Organization
171 N954651e6f8874d3ea4081f4786d0603f schema:volumeNumber 7
172 rdf:type schema:PublicationVolume
173 N95740e22558e462787f8ebc7cd15910b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Fluorodeoxyglucose F18
175 rdf:type schema:DefinedTerm
176 N95ffcd96ccaa463bbb0e3fadf22b1fae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Middle Aged
178 rdf:type schema:DefinedTerm
179 N9a9fc826aca44818ba1fb0bbc48773a7 rdf:first sg:person.07500134657.59
180 rdf:rest N74d6bb825ae1410dad02701c8ac5dec5
181 Nb2a49fbe767f407386a526556d898dc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Proportional Hazards Models
183 rdf:type schema:DefinedTerm
184 Nb502f5384df24b8d9122421517f8c9f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Tomography, X-Ray Computed
186 rdf:type schema:DefinedTerm
187 Nb525c098f6694229a0385e72054162c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Multimodal Imaging
189 rdf:type schema:DefinedTerm
190 Nccf88d4985ed4d93b5bf96aa6af3e016 rdf:first sg:person.01255207421.15
191 rdf:rest N46af97ead2ac476ca0b1afb5a0074a2e
192 Ncf11bb1275ac4cc6a7548ce1c53703df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Humans
194 rdf:type schema:DefinedTerm
195 Nd92211fce71b49b58b16209c6c665e68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Adult
197 rdf:type schema:DefinedTerm
198 Nf5307e6b27a14aa89687ecdcf04b4ae8 rdf:first sg:person.014351135104.56
199 rdf:rest rdf:nil
200 Nfcc4fb8730cb412d81b53fd471bf5c4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Carcinoma, Non-Small-Cell Lung
202 rdf:type schema:DefinedTerm
203 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
204 schema:name Medical and Health Sciences
205 rdf:type schema:DefinedTerm
206 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
207 schema:name Oncology and Carcinogenesis
208 rdf:type schema:DefinedTerm
209 sg:grant.2435408 http://pending.schema.org/fundedItem sg:pub.10.1186/1748-717x-7-144
210 rdf:type schema:MonetaryGrant
211 sg:grant.2438826 http://pending.schema.org/fundedItem sg:pub.10.1186/1748-717x-7-144
212 rdf:type schema:MonetaryGrant
213 sg:journal.1036451 schema:issn 1748-717X
214 schema:name Radiation Oncology
215 schema:publisher Springer Nature
216 rdf:type schema:Periodical
217 sg:person.01006443300.49 schema:affiliation grid-institutes:grid.240145.6
218 schema:familyName Erasmus
219 schema:givenName Jeremy
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006443300.49
221 rdf:type schema:Person
222 sg:person.01255207421.15 schema:affiliation grid-institutes:grid.240145.6
223 schema:familyName Xiang
224 schema:givenName Zuo-Lin
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255207421.15
226 rdf:type schema:Person
227 sg:person.014351135104.56 schema:affiliation grid-institutes:grid.240145.6
228 schema:familyName Chang
229 schema:givenName Joe Y
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014351135104.56
231 rdf:type schema:Person
232 sg:person.0734411024.14 schema:affiliation grid-institutes:grid.240145.6
233 schema:familyName Cox
234 schema:givenName James D
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734411024.14
236 rdf:type schema:Person
237 sg:person.07500134657.59 schema:affiliation grid-institutes:grid.240145.6
238 schema:familyName Komaki
239 schema:givenName Ritsuko
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07500134657.59
241 rdf:type schema:Person
242 sg:pub.10.1186/1748-717x-4-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035283096
243 https://doi.org/10.1186/1748-717x-4-5
244 rdf:type schema:CreativeWork
245 grid-institutes:grid.240145.6 schema:alternateName Departments of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
246 Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
247 schema:name Departments of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
248 Departments of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
249 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...